Skip to main content
CNTB
NASDAQ Life Sciences

Connect Biopharma's Rademikibart Phase 2 Asthma/COPD Trials Progress as Planned After Positive Interim Review

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.68
Mkt Cap
$146.955M
52W Low
$0.65
52W High
$3.82
52W Position info
312% above low
Off High info
30% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

CNTB has more than doubled off its 52-week low of $0.65.

Summary

Connect Biopharma announced that an independent Data Monitoring Committee completed its interim review of Phase 2 trials for rademikibart in asthma and COPD, recommending no changes to sample size, indicating positive trial progression and safety.


Key Events · Product Development and Regulatory · CNTB

  • Phase 2 Rademikibart Trials Progress

    The independent Data Monitoring Committee (DMC) completed its pre-specified interim analysis of efficacy for the Phase 2 Seabreeze STAT asthma and COPD trials evaluating rademikibart.

  • No Sample Size Change Recommended

    The DMC recommended no change in sample size, indicating that enrollment will continue as planned, which is a positive signal for trial progression.

  • Positive Safety Profile Noted

    Rademikibart continues to be well tolerated in the studies, with no treatment-related serious adverse events or discontinuations due to adverse events reported to date.

  • Topline Data Expected Mid-2026

    The company remains on track to report topline results from both Seabreeze STAT studies in mid-2026, with plans to engage the FDA for a Phase 3 program.


Analysis · CNTB · Life Sciences

This 8-K reports a crucial interim milestone for Connect Biopharma's lead asset, rademikibart. The Data Monitoring Committee's decision to continue the Phase 2 Seabreeze STAT trials for asthma and COPD without recommending changes to the sample size is a positive signal, suggesting no significant safety concerns or lack of efficacy were identified at this stage. For a clinical-stage biopharmaceutical company, successful progression through trials is paramount, especially given the company's recent financial performance. This update de-risks the program somewhat and maintains the timeline for topline data in mid-2026, which will be a significant catalyst for the stock.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CNTB was trading at $2.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $147M. The 52-week trading range was $0.65 to $3.82. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CNTB - Latest Insights

CNTB
Nov 16, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.643
Real-time Price: $0.580 info
Change: -$0.063 (-10%) info
Market Cap: $38.048M info
CNTB
Sep 30, 2026, 7:07 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $1.03
Real-time Price: $0.580 info
Change: -$0.450 (-44%) info
Market Cap: $38.048M info
CNTB
Sep 30, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.09
Real-time Price: $0.580 info
Change: -$0.510 (-47%) info
Market Cap: $38.048M info
CNTB
Sep 15, 2026, 11:46 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $1.11
Real-time Price: $0.580 info
Change: -$0.5297 (-48%) info
Market Cap: $38.048M info
CNTB
Sep 15, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.73
Real-time Price: $0.580 info
Change: -$1.15 (-66%) info
Market Cap: $38.048M info